Valeo Chalks Up Another Milestone For Canadian Enoxaparin Biosimilars
Follows Backing To Be Listed On The Quebec Public Health Plan
Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.
You may also be interested in...
Sandoz Canada has taken another “important step as we pursue our ambition to become the leading biosimilars and generics company” with the launch of biosimilar enoxaparin.
Canadian firm Valeo Pharma is looking to make a splash with enoxaparin biosimilars, Redesca and Redesca HP, following approval from Health Canada.
Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.